2020
Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI
Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. European Radiology 2020, 31: 2737-2746. PMID: 33123796, PMCID: PMC8043967, DOI: 10.1007/s00330-020-07381-9.Peer-Reviewed Original ResearchConceptsTumor response criteriaOverall survivalAdvanced-stage HCCDisease progressionSorafenib therapyDisease controlResponse criteriaCox proportional hazards regression modelAdvanced-stage hepatocellular carcinomaProportional hazards regression modelsDCE-MRIInitiation of sorafenibTumor response analysisMultivariable Cox regressionIndependent risk factorMethodsThis retrospective analysisIndependent prognostic factorInitiation of treatmentKaplan-Meier analysisKaplan-Meier curvesHazards regression modelsLog-rank testStratification of patientsTotal tumor volumeArterial phase MRI
2019
Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Ippolito D, Querques G, Pecorelli A, Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Journal Of Computer Assisted Tomography 2019, Publish Ahead of Print: &na;. PMID: 30407241, DOI: 10.1097/rct.0000000000000807.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaProgressive diseasePartial responseDynamic contrast-enhanced perfusionPerfusion CT valuesHepatic perfusion indexResponse Evaluation CriteriaMultifocal hepatocellular carcinomaIntravenous bolus injectionBlood flow changesContrast-enhanced perfusionRow Computed TomographyPerfusion CT techniquesStandard of referenceNonprogressor groupProgressor groupSorafenib administrationCirrhotic patientsArterial perfusionHepatic perfusionPD patientsTumor responsePerfusion indexTherapeutic response
2018
Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions
Ippolito D, Querques G, Okolicsanyi S, Franzesi C, Pecorelli A, Lombardi S, Orsini E, Strazzabosco M, Sironi S. Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions. European Journal Of Radiology 2018, 106: 62-68. PMID: 30150052, DOI: 10.1016/j.ejrad.2018.07.012.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaAnti-angiogenic therapyPerfusion CT imagingHepatocellular carcinomaPerfusion parametersProgressor groupSurvival rateNon-progressor groupOverall survival rateKaplan-Meier analysisAssessment of responseAntiangiogenetic treatmentCirrhotic patientsSorafenib administrationPrognostic indicatorTumor responseTarget lesionsHCC lesionsIndividualized treatmentTumor neoangiogenesisPatientsOverall populationHigher survival rateCT imagingSurvival prediction
2015
Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation
Morton SD, Cadamuro M, Brivio S, Vismara M, Stecca T, Massani M, Bassi N, Furlanetto A, Joplin RE, Floreani A, Fabris L, Strazzabosco M. Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation. Oncotarget 2015, 6: 26052-26064. PMID: 26296968, PMCID: PMC4694885, DOI: 10.18632/oncotarget.4482.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsApoptosisBile Duct NeoplasmsBlotting, WesternCell Line, TumorCholangiocarcinomaCisplatinDeoxycytidineGemcitabineGene Expression Regulation, NeoplasticHumansLeukemia Inhibitory FactorLeukemia Inhibitory Factor Receptor alpha SubunitMicroscopy, FluorescenceMyeloid Cell Leukemia Sequence 1 ProteinPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReverse Transcriptase Polymerase Chain ReactionRNA InterferenceSignal TransductionConceptsLeukemia inhibitory factorDrug-induced apoptosisChemotherapy-induced apoptosisPI3K inhibitionLIF effectsLIFR expressionExpression of LIFInhibitory factorRole of LIFCholangiocarcinoma cellsK inhibitionPI3K/Akt-dependent pathwayTumor stromal cellsHuman cholangiocarcinoma cell linesCell-like phenotypeCholangiocarcinoma cell linesMcl-1Akt-dependent pathwayUp-regulating Mcl-1IL-6 family cytokinesLIF secretionLiver malignanciesCholangiocarcinoma cell proliferationAnti-apoptotic proteinsFamily cytokines
2013
Platelet‐derived growth factor‐D and Rho GTPases regulate recruitment of cancer‐associated fibroblasts in cholangiocarcinoma
Cadamuro M, Nardo G, Indraccolo S, Dall'Olmo L, Sambado L, Moserle L, Franceschet I, Colledan M, Massani M, Stecca T, Bassi N, Morton S, Spirli C, Fiorotto R, Fabris L, Strazzabosco M. Platelet‐derived growth factor‐D and Rho GTPases regulate recruitment of cancer‐associated fibroblasts in cholangiocarcinoma. Hepatology 2013, 58: 1042-1053. PMID: 23505219, PMCID: PMC3732815, DOI: 10.1002/hep.26384.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBenzamidesBile Duct NeoplasmsBile Ducts, IntrahepaticCell Line, TumorCell MovementCell ProliferationCells, CulturedCholangiocarcinomaEpithelial-Mesenchymal TransitionFibroblastsHeterograftsHumansImatinib MesylateIn Vitro TechniquesLymphokinesMaleMiceMice, SCIDPiperazinesPlatelet-Derived Growth FactorPyrimidinesRho GTP-Binding ProteinsSignal TransductionConceptsCancer-associated fibroblastsPlatelet-derived growth factorEpithelial-mesenchymal transitionCCA cellsSecretion of PDGFRole of PDGFGrowth factorAbundant stromal reactionAlpha-smooth muscle actinPDGF-D expressionNovel therapeutic approachesPotential therapeutic targetSmooth muscle actinCCA cell linesPDGF-D signalingFibroblast migrationC-Jun N-terminal kinaseEMT biomarkersImmunodeficient miceStromal reactionTherapeutic approachesStroma interactionsTherapeutic targetCholangiocarcinomaMesenchymal markers
2011
Systemic Therapy in Hepatocellular Carcinoma
Wrzesinski SH, Taddei TH, Strazzabosco M. Systemic Therapy in Hepatocellular Carcinoma. Clinics In Liver Disease 2011, 15: 423-441. PMID: 21689622, PMCID: PMC3758582, DOI: 10.1016/j.cld.2011.03.002.BooksMeSH KeywordsAnimalsAntineoplastic AgentsCarcinoma, HepatocellularClinical Trials as TopicHumansLiver NeoplasmsLiver Neoplasms, Experimental